Terns, Inc. clinical trials
Acquired by Merck & Co., Inc, May 5, 2026 · source ↗
The registry lists 7 studies whose lead sponsor is Terns, Inc. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
- 7studies on the registry
- 1open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Terns, Inc. became part of Merck & Co., Inc
- 5
- First submitted after Terns, Inc. became part of Merck & Co., Inc
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Terns, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 120
- 21
- 22
- 23
- 24
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 studies
- Terns, Inc.3 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Merck & Co., Inc studies →
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)RecruitingNCT06163430Phase 1/2
Sponsor listed in the registry: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Terns, Inc. became part of Merck & Co., Inc
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)CompletedNCT07838987Phase 1
Sponsor listed in the registry: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted after Terns, Inc. became part of Merck & Co., Inc
- A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)CompletedNCT07839000Phase 1
Sponsor listed in the registry: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted after Terns, Inc. became part of Merck & Co., Inc
- A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityCompletedNCT06854952Phase 2
Sponsor listed in the registry: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Terns, Inc. became part of Merck & Co., Inc
- DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisCompletedNCT05415722Phase 2
Sponsor listed in the registry: Terns, Inc. · First submitted before Terns, Inc. became part of Merck & Co., Inc
- AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic SteatohepatitisCompletedNCT04897594Phase 1
Sponsor listed in the registry: Terns, Inc. · First submitted before Terns, Inc. became part of Merck & Co., Inc
- LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)CompletedNCT04328077Phase 2
Sponsor listed in the registry: Terns, Inc. · First submitted before Terns, Inc. became part of Merck & Co., Inc